COVID-19 vaccine trials in Africa
On Aug 17, 2020, screening began for participants to enrol in the mid-stage study of an experimental COVID-19 vaccine by Novavax, a US drug developer of next-generation vaccines for serious infectious diseases, at Witwatersrand University (Wits) in Johannesburg, South Africa. A US$15 million grant t...
- Autores:
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13208
- Acceso en línea:
- https://www.sciencedirect.com/science/article/pii/S221326002030401X
http://hdl.handle.net/20.500.12010/13208
https://doi.org/10.1016/S2213-2600(20)30401-X
- Palabra clave:
- COVID-19
Vaccines
COVID-19
- Rights
- License
- Acceso restringido
| id |
UTADEO2_bdb3d3456134196a1e039548d5a3f238 |
|---|---|
| oai_identifier_str |
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13208 |
| network_acronym_str |
UTADEO2 |
| network_name_str |
Expeditio: repositorio UTadeo |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
COVID-19 vaccine trials in Africa |
| title |
COVID-19 vaccine trials in Africa |
| spellingShingle |
COVID-19 vaccine trials in Africa COVID-19 Vaccines COVID-19 |
| title_short |
COVID-19 vaccine trials in Africa |
| title_full |
COVID-19 vaccine trials in Africa |
| title_fullStr |
COVID-19 vaccine trials in Africa |
| title_full_unstemmed |
COVID-19 vaccine trials in Africa |
| title_sort |
COVID-19 vaccine trials in Africa |
| dc.subject.spa.fl_str_mv |
COVID-19 |
| topic |
COVID-19 Vaccines COVID-19 |
| dc.subject.keyword.spa.fl_str_mv |
Vaccines COVID-19 |
| description |
On Aug 17, 2020, screening began for participants to enrol in the mid-stage study of an experimental COVID-19 vaccine by Novavax, a US drug developer of next-generation vaccines for serious infectious diseases, at Witwatersrand University (Wits) in Johannesburg, South Africa. A US$15 million grant towards the trial was awarded to Novavax by the Bill & Melinda Gates Foundation. 2665 healthy adults and nearly 240 medically stable, HIV-positive adults will be enrolled. |
| publishDate |
2020 |
| dc.date.accessioned.none.fl_str_mv |
2020-09-12T14:34:27Z |
| dc.date.available.none.fl_str_mv |
2020-09-12T14:34:27Z |
| dc.date.created.none.fl_str_mv |
2020-09-05 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| format |
http://purl.org/coar/resource_type/c_6501 |
| dc.identifier.issn.spa.fl_str_mv |
2213-2600 |
| dc.identifier.other.spa.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S221326002030401X |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12010/13208 |
| dc.identifier.doi.spa.fl_str_mv |
https://doi.org/10.1016/S2213-2600(20)30401-X |
| identifier_str_mv |
2213-2600 |
| url |
https://www.sciencedirect.com/science/article/pii/S221326002030401X http://hdl.handle.net/20.500.12010/13208 https://doi.org/10.1016/S2213-2600(20)30401-X |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_f1cf |
| dc.rights.local.spa.fl_str_mv |
Acceso restringido |
| rights_invalid_str_mv |
Acceso restringido http://purl.org/coar/access_right/c_f1cf |
| dc.format.extent.spa.fl_str_mv |
2 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
The Lancet |
| institution |
Universidad de Bogotá Jorge Tadeo Lozano |
| bitstream.url.fl_str_mv |
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13208/2/license.txt https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13208/4/Captura.JPG https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13208/5/COVID-19-vaccine-trials-in-Africa_2020_The-Lancet-Respiratory-Medicine.pdf.jpg https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13208/3/COVID-19-vaccine-trials-in-Africa_2020_The-Lancet-Respiratory-Medicine.pdf |
| bitstream.checksum.fl_str_mv |
abceeb1c943c50d3343516f9dbfc110f 124f7708e6bd85ce0efb21988f8cf7a4 2d77451cfe837964aa52d7522b9dbe51 450e9c576619040a59249d9e19f7bdec |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional - Universidad Jorge Tadeo Lozano |
| repository.mail.fl_str_mv |
expeditio@utadeo.edu.co |
| _version_ |
1814213649411080192 |
| spelling |
2020-09-12T14:34:27Z2020-09-12T14:34:27Z2020-09-052213-2600https://www.sciencedirect.com/science/article/pii/S221326002030401Xhttp://hdl.handle.net/20.500.12010/13208https://doi.org/10.1016/S2213-2600(20)30401-X2 páginasapplication/pdfengThe LancetCOVID-19VaccinesCOVID-19COVID-19 vaccine trials in AfricaAcceso restringidohttp://purl.org/coar/access_right/c_f1cfOn Aug 17, 2020, screening began for participants to enrol in the mid-stage study of an experimental COVID-19 vaccine by Novavax, a US drug developer of next-generation vaccines for serious infectious diseases, at Witwatersrand University (Wits) in Johannesburg, South Africa. A US$15 million grant towards the trial was awarded to Novavax by the Bill & Melinda Gates Foundation. 2665 healthy adults and nearly 240 medically stable, HIV-positive adults will be enrolled.http://purl.org/coar/resource_type/c_6501Makoni, MunyaradziLICENSElicense.txtlicense.txttext/plain; charset=utf-82938https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13208/2/license.txtabceeb1c943c50d3343516f9dbfc110fMD52open accessTHUMBNAILCaptura.JPGCaptura.JPGimage/jpeg89356https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13208/4/Captura.JPG124f7708e6bd85ce0efb21988f8cf7a4MD54open accessCOVID-19-vaccine-trials-in-Africa_2020_The-Lancet-Respiratory-Medicine.pdf.jpgCOVID-19-vaccine-trials-in-Africa_2020_The-Lancet-Respiratory-Medicine.pdf.jpgIM Thumbnailimage/jpeg23631https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13208/5/COVID-19-vaccine-trials-in-Africa_2020_The-Lancet-Respiratory-Medicine.pdf.jpg2d77451cfe837964aa52d7522b9dbe51MD55open accessORIGINALCOVID-19-vaccine-trials-in-Africa_2020_The-Lancet-Respiratory-Medicine.pdfCOVID-19-vaccine-trials-in-Africa_2020_The-Lancet-Respiratory-Medicine.pdfDocumento reservadoapplication/pdf354891https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13208/3/COVID-19-vaccine-trials-in-Africa_2020_The-Lancet-Respiratory-Medicine.pdf450e9c576619040a59249d9e19f7bdecMD53embargoed access|||2220-09-0120.500.12010/13208oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/132082020-09-12 09:35:31.466embargoed access|||2220-09-01Repositorio Institucional - Universidad Jorge Tadeo Lozanoexpeditio@utadeo.edu.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 |